Estrogen-only HRT continues to protect women against breast cancer long after they have stopped

March 6, 2012, Lancet

Women who use the oestrogen-only form of hormone replacement therapy (HRT) appear less likely to develop breast cancer in the longer term, according to new research published Online First in The Lancet Oncology. A follow-up study of over 7500 women from the Women's Health Initiative (WHI) trial who took oestrogen for about 6 years and then stopped has found that they are over 20% less likely to develop breast cancer and remain significantly less likely to die from the disease than those who never used HRT, a period of nearly 5 years after stopping treatment.

"These latest results should provide reassurance about breast safety of oestrogen use for durations of about 5 years for women with a hysterectomy seeking relief from postmenopausal symptoms", explains Garnet Anderson from the Fred Hutchinson Cancer Research Center, Seattle, USA, lead author of the study.

In 1993, the WHI trial of oestrogen alone was established to investigate the effects of conjugated equine oestrogen on chronic disease. Nearly 11 000 postmenopausal women aged 50 to 79 years old who had previously had a were given oestrogen or placebo over a period of nearly 7 years. The trial was stopped in 2004 (a year earlier than planned) because of an increased risk of stroke and .

In this new analysis, Anderson and colleagues report the overall effects of oestrogen use on incidence and mortality, including extended follow-up of 7645 women (78% of the original surviving members) who were tracked from March 2005 until August 2009, a median (midpoint) 4.7 years after stopping oestrogen therapy.

The researchers found a 23% reduction in the incidence of compared with placebo (151 cases, 0.27% per year vs 199 cases, 0.35% per year) during an overall follow-up period of nearly 12 years, whilst women in the oestrogen group who did develop breast cancer had a 63% reduction in deaths from the disease (six deaths, 0.009% per year vs 16 deaths, 0.024% per year) compared with those in the placebo group.

The lower risk of breast cancer was restricted to women without a history of benign breast disease or a strong family history of breast cancer. They say: "The continued postintervention effect of oestrogen on breast cancer incidence is akin to that reported for other hormone-targeted drugs shown to reduce breast cancer incidence."

However, they caution: "Our data do not support the use of oestrogen for breast cancer risk reduction in light of the lack of benefit noted in populations at higher risk (including those with a strong family history of breast cancer or benign breast disease) and the additional risk of stroke and blood clots."

In an accompanying Comment Anthony Howell from the University Hospital of South Manchester, UK, and Jack Cuzick from Queen Mary, University of London say: "The WHI investigators should be congratulated for providing insight concerning the value of CEE and young can be reassured of the low risks and potentially striking benefits, provided that they are counselled about the small increases in thromboembolic disease as noted with most hormonal preparations."

Explore further: Women should still be concerned about hormone replacement therapy, researchers say

Related Stories

Women should still be concerned about hormone replacement therapy, researchers say

December 21, 2011
McMaster University researchers have found consistent evidence that use of hormone replacement therapy (HRT) is associated with breast cancer globally. This study comes at a time when more women are again asking for this ...

New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy

September 26, 2011
Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome. Researchers ...

Male breast cancer patients stop taking tamoxifen early because of drug-related side effects

November 16, 2011
The largest study to investigate the tolerability of the breast cancer drug tamoxifen in male breast cancer patients has shown that men stop taking their prescribed therapy early because of problems with side effects caused ...

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.